211At-BCMA-B10

211At-BCMA-B10 is a targeted alpha therapy (TAT) consisting of a human IgG1 monoclonal antibody directed against B-cell maturation antigen (BCMA) conjugated with the alpha-emitting radioisotope astatine-211 (211At) using the B10-NCS labeling agent. Developed by researchers at the Fred Hutchinson Cancer Center, this radiopharmaceutical is designed to treat multiple myeloma by delivering high-energy alpha particles directly to malignant plasma cells. The alpha radiation induces irreparable double-stranded DNA breaks within a short range (50-90 μm), which minimizes damage to surrounding healthy tissue while effectively killing target-positive cells and potentially nearby target-negative cells through a bystander effect. Preclinical studies have demonstrated high efficacy in eliminating minimal residual disease in mouse xenograft models, showing superior results compared to other targeted radiotherapies like 211At-CD38.

Other names

astatine-211-labeled anti-BCMA antibodyastatine211-labeled anti-BCMA antibodyastatine 211-labeled anti-BCMA antibody211At-labeled anti-BCMA mAb